Plain-English translation of NCT06708949 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding a third immunotherapy drug called relatlimab to a two-drug combination (nivolumab and ) works better for treating advanced kidney cancer. These are all immunotherapy medications that help your body's immune system fight cancer. The study wants to see if the three-drug combination is safer and more effective than the two-drug combination alone.
Advanced kidney cancer is a serious condition that spreads to other parts of the body. While two-drug immunotherapy combinations have helped some patients, doctors want to know if adding a third drug could help more people or work better. This trial will help answer that question.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive one of two treatment combinations given as outpatient infusions. This means you'll come to the clinic for injections but won't need to stay in the hospital. Your doctor will monitor you closely with regular blood tests and scans to see how well the treatment is working and to watch for any side effects. The study is small, enrolling about 15 people total, so you'll receive careful individualized attention.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States